Seroepidemiological Investigation of Coronavirus 2019 (COVID-19) Infection in Gabon

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

3455 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gabon is the 3rd country most affected by COVID-19 behind Cameroon and Democratic Republic of Congo in Central Africa, with 8860 cases and 54 deaths in critically ill patients, since the first confirmed case of COVID-19 on the 10th of March 2020 (https://africacdc.org/covid-19/). Most of the individuals infected by SARS-CoV-2 are asymptomatic and they represent a major source of viral spread. To date, African countries have been less affected by deaths caused by the Covid-19 pandemic compared to other countries. It is currently unknown why Africa has avoided more deaths and appears to not simply be due to a lack of testing, since the overall death rate has not increased. Better quality data on seroprevalence in different African regions and proven explanations of the differences between Africa and other continents, are urgently needed. The aim of this study is to learn about the proportion of people after a first pic of transmission, who have been exposed to COVID-19 in Gabon by testing for plasma antibodies to the SARS-CoV-2 virus.

The overall goal of this study is to examine the trend of specific anti-SARS-CoV-2 antibodies in Gabonese population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COVID-19 STAndard of Care in Sub-Saharan Africa

NCT04885543

Covid19

COMPLETED

Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC

NCT04235361

Ebola Virus Disease Malaria Typhoid Fever +3 more

UNKNOWN

Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response

NCT04250168

Sepsis Bacterial Ebola Virus Disease Bloodstream Infection

TERMINATED

Africa COVID-19 Vaccine Hesitancy

NCT04912284

Covid19

COMPLETED

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

NCT04832932

COVID-19 Vaccines

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on its technical capacities (ELISA bench and multiparametric flow cytometer), we will provide evident data on the immune responses in Covid-19 infected patients. The quantification of antibodies against SARS-CoV-2 recombinant protein will be done by ELISA using Wantai ELISA total Ab. Meanwhile, data on clinical status will be recorded and classified using WHO patient form. Data obtained will be analyzed by a statistician based at CERMEL using robust models in compliance with the type of data generated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laboratory Confirmed SARS-CoV-2 Infection Without Symptoms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.